Rapid in vivo screening method for the evaluation of new anti Helicobacter medicinal preparations

African Journal of Traditional, Complementary and Alternative Medicines

Volumn 3, Issue 4, 2006, Pages 102-114

  Boda, Maurice ^a   Tan, Paul V ^a   Nyasse, Barthelemy ^a  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

Author keywords

Helicobacter pylori; In vivo; Mouse model

Indexed keywords

7,8 DIHYDRO 8 HYDROXYPALMATINE; AMOXICILLIN; AMOXYL; ANTIINFECTIVE AGENT; METRONIDAZOLE; TABERSONINE; UNCLASSIFIED DRUG; UREASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CELL PROTECTION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; ERADICATION THERAPY; EXPERIMENTAL MODEL; FEMALE; GRAM STAINING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; INTESTINE FLORA; MALE; MOUSE; NONHUMAN; STOMACH ANTRUM; ULCER HEALING;

EID: 33751018887     PISSN: 01896016     EISSN: 01896016     Source Type: Journal    
DOI: 10.4314/ajtcam.v3i4.31182     Document Type: Article

References (44)

1. Beales, Ian L.P. (2001). Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC Gastroentorology: 1: 1-9.
2. Best L. M., Haldane D. J. M., Keelan M., Taylor D. E., Thomson A. B. R., Loo V., Fallone C. A., Lun P., Smaill F. M., Hunt R., Gaudreau C., Kenedy J., Alfa M., Pelletier R., Veldhuyzen van Zanten S. J. O. (2003). Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E Test methods. Antimicrob Agents Chemother. 47(10):3138-3144.
3. Blaser N. J. (1997). Not all Helicobacter pylori strains are created equal: should all be eliminated? Lancet 349: 1020-1022.
4. CCUG Web site (a). Microaerophilic growth conditions for most Helicobacters. http://www.ccug.gu.se/default.cfm?navID=14 (27 February 2006, date last accessed).
5. CCUG Web site (b). CCUG database selected: Microorganisms (strains). http://www.ccug.se/default.cfm?page=search_record.cfm&id= 12610&db=mc (27 February 2006, date last accessed).
6. Cheesbrough M. (2000). Microbiological tests. In District Laboratory Practice in Tropical Countries Part 2 Cheesbrough M; editor. Cambridge Low Price Edition. p. 45-157.
7. Danon J. S., O'Rourke L. L., Moss D. N., Lee A. (1995). The importance of local acid production in the distribution of Helicobacter felis in mouse stomach. Gastroenterology. 108: 1386-1395.
8. DeCross A. J., Marshall B. J. (1993). The role of Helicobacter pylori in acid-peptic disease. Am. J. Med. Sci. 306: 381-391.
9. Dunn B. E., Cohen H., Blaser M. J. (1997). Helicobacter pylori. Clin. Microbiol. Rev. 10(4):720-741
10. Enno A., O'Rourke J. L., Howlett R. C., Andrew J., Dixon M. F., Lee A. (1995). MALToma-like lesion in murine gastric mucosa after-long-term infection with Helicobacter felis. A mouse model of Helicobacter pylori - induced gastric lymphoma. Am. J. Pathol. 147(1): 217-222.
11. Fauchere J. L. (1999). Bacteriological characteristics and diagnosis of Helicobacter pylori Laborama. 6: 10-14.
12. Fox G. J., Batchelder M., Marini R., Yan L., Handt L., Li x., Shames B., Hayward A., Campbell J., Murphy J. C. (1995). Helicobacter pylori-induced gastritis in domestic cats. Infect. Immun. 63(7): 2674-2681.
13. Gibson J. R., Saunders N. A., Burke B., Owen R. J. (1999). Novel method for rapid determination of Clarithromycin sensitivity in Helicobacter pylori. J. Clin. Microbiol. 37 (11): 3746-3748
14. Graham D. Y. (1997). Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 113: 1983-1991.
15. Haas, C.E., Nix, D.E., Schentag, J.J. (1990). In vitro selection of resistant Helicobacter pylori. Antimicrob. Agents Chemother. 34: 1637-1640.
16. Hassan J. I., Stark M. R., Greenman, J., Millar, R. M. (1999). Activity of β-Lactams and Macrolides against Helicobacter pylori. Antimicrob Agents Chemother. 43(6): 1387-1392.
17. Hentschel E. G., Brandstatter B., Dragosics A. M., Hirschl H., Nemec K, Schutze M., Wurzer H.( 1993). Effet of ranitidine and Amoxicillin plus Metronidazole on the eradication of H. pylori and recurrence of duodenal ulcer. N. Engl. J. Med. 328: 308-312.
18. Jenks P. J., Labigne A., Ferrero R. L. (1999). Exposure to Metronidazole In Vivo Readily Induces Resistance in Helicobacter pylori and Reduces the Efficacy of Eradication Therapy in Mice. Antimicrob. Agents Chemother. 43(4): 777-781.
19. Kanamaru T., Nakano Y., Toyoda Y., Ken-Ichiro M., Mayumi T., Tomoko K., Masafumi N. (2001). In Vitro and In Vivo Antibacterial Activities of TAK-083, an Agent for Treatment of Helicobacter pylori Infection. Antimicrob Agents Chemother. 45 (9): 2455-2459.
20. Kato M., Yamaoka Y., Jae J. K., Reddy R., Asaka M., Kashima K., Osato M. S., El-Zaatari K. A. F., Graham Y. D. Kwon H. D. (2000). Regional Differences in Metronidazole Resistance and Increasing Clarithromicin Resistance among Helicobacter pylori Isolates from Japan. Antimicrob Agents Chemother. 44(8): 2214-2216.
21. Krakowka S., Eaton K. A. and Leunk D. R. (1998). Antimicrobial therapies for Helicobacter pylori Infection in Gnotobiotic piglets. Antimicrob Agents Chemother. 42(7): 1549-1554.
22. Lee A. O'Rourke J., De Ungria M. C., Bronwyn R., Daskalopoulos G., Dixon F. M. (1997). A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney strain. Gastroenterology. 112(4): 1386-1397.
23. Lee A. (1998). Animal models for host-pathogen interaction studies. Brit. Med bull. 54 (1): 163-173.
24. Loughlin M. F., Ala'Aldeen D. A., Jenks J. P. (2003). Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice. J. Antimicrobial Chemother. 51: 367-371.
25. Mahady G. B., Pendland S. L.,Yun S. G., Zhi-Zhen L., Stoia A. (2003a). Ginger (Zingiber Officlinale Rsocoe) and the Ginerol Inhibit the growth of cag A+ Strains of helicobacter pylori. Anticancer Research: 23: 3699-3702.
26. Mahady G. B., Pendland S. L., Stoia A., Chadwick R. L. (2003b). In vitro susceptibity of Helicobacter pylori to Isoquinoline Alkaloids from Sanguinara canadensis and Hydrastis canadensis. Phytother. Res. 17: 217-221.
27. Marone P., Bono L., Leone E., Bona S., Carretto E. and Perversi, L. (2001). Bactericidal activity of Pistacia lentiscus mastic gum against Helicobacter pylori. J. Chemother. 13: 611-614.
28. Nataliya I. B., Yoon Y. J., Kim K. (2000). Inhibition of Helicobacter pylori Hemagglutination by polysaccharide fractions from the roots of Panax ginseng. Planta Medica. 66: 217-220.
29. Niyaz A.n Sechi A. L. (2005). Helicobacter pylori and gastroduodenal pathology: New threads of the old friend. An Clin. Microbiol. Antimicrob. 4 (1): 1-10.
30. Okamoto T., Yoshiyama H., Nakazawal T., In-Dal P., Myung-Woong C., Yanai H., Okita K., Shirail M. (2002). A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother. 50: 849-856.
31. Radcliff F.J., Chen M., Lee A. (1996). Protective immunization against Helicobacter stimulates long-term immunity. Vaccine. 4(8):780-784.
32. Sakagami T., Dixon M, O'Rourke J., Howlett R., Alderuccio F., Vella J., Shimoyama T., Lee A. ( 1996). Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. GUT. 39(5): 369-348.
33. Sgouras D., Maragkoudakis P., Petraki K., Martinez-Gonzalez B., Eriotou E., Michopoulos S., Kalantzopoulos G., Tsakalidou E. and Mentis A. (2004). In Vitro and In Vivo Inhibition of Helicobacter pylori by Lactobacillus casei Strain Shirota Ap. Environ. Microbiol. 70 (1): 548-526.
34. Sjöström J. E., Kühler T., Larsson H. (1997). Basis for the Selective Antibacterial Activity In Vitro of Proton Pump Inhibitors against Helicobacter spp. Antimicrob Agents Chemother. 41(8): 1797-1801.
35. Skirrow M.B. (1992). Campylobacter and Helicobacter enteritis; gastritis in Medical Microbiology Greenwood et al., editors. 14th edition; ELBS edition. p. 353-361.
36. Svensson M., Ström M., Nilson M., Sörberg M., Nilson L. E. (2002). Pharmacodynamic effects of Nitoimidazoles alone and in combination with Clrithromycin on Helicobacter pylori. Antimicrob Agents Chemother. 46(7): 2244-2248.
37. Takeshi Okamoto, Hironori Yoshiyamal, Teruko Nakazawal, In-Dal Park, Myung-Woong Chang, Hideo Yanai, Kiwamu Okita, Mutsunori Shirai. (2002). A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J. Antimicrob. Chemother. 50: 849-856
38. Tan, P. V., Nyasse, B., Enow-Orock, G.E., Wafo, P., Forcha, E.A. (2000). Prophylactic and healing properties of a new anti-ulcer compound from Enantia chlorantha in rats. Phytomedicine 7(4): 291-296.
39. Tan, P.V., Nyasse, B., Dimo J., Wafo, P., Akahkuh, B.T. (2002). Synergistic and potentiating effects of ranitidine and two new anti-ulcer compounds from Enantia chlorantha and Voacanga africana in experimental animal models. Pharmazie 57(6): 409-412.
40. 2 receptor blocking activity. Phytomedicine 7(6): 509-515.
41. Van Doorn, H.Y., Nouhan, N., Verschuuren, A., Vreede, R., Herbink, P., Ponjee, G., Van Krimpen, K., Blankenburg, R., Scherpenisse, J., Quint, W. (2000). The efficacy of laboratory diagnosis of Helicobacter pylori infection in gastric biopsy specimens is related to bacterial density and vacA, cagA, and iceA genotypes: J. Clin. Microbiol. 38:13-17.
42. Wafo, P., Nyasse, B., Fontaine, C A. (1999). 7,8-dihidro-8- hydroxypalmatine from Enantia chlorantha. Phytochemistry. 50: 279-281.
43. Walsh J. H., Peterson W. L. (1995). The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N. Engl. J. Med. 333: 984-991.
44. Yee. Y. K., Koo M. W. (2000). Anti-Helicobacter pylori of Chinese tea: In vitro study. Aliment. Pharmacol. Ther. 14:615-618.